Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2015; 7(3): 548-558
Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.548
Hepatitis C in hemodialysis patients
Smaragdi Marinaki, John N Boletis, Stratigoula Sakellariou, Ioanna K Delladetsima
Smaragdi Marinaki, John N Boletis, Department of Nephrology and Renal Transplantation Unit, Medical School, University of Athens, Laiko General Hospital, 11527 Athens, Greece
Stratigoula Sakellariou, Ioanna K Delladetsima, First Department of Pathology, Medical School, University of Athens, 11527 Athens, Greece
Author contributions: Delladetsima IK designed research; Marinaki S and Sakellariou S performed research; Boletis JN and Sakellariou S contributed new reagents or analytic tools; Marinaki S analyzed data; Marinaki S and Delladetsima IK wrote the paper.
Conflict-of-interest: None declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Ioanna K Delladetsima, Associate Professor, First Department of Pathology, Medical School, University of Athens, 75 Mikras Asias Str, Goudi, 11527 Athens, Greece.
Telephone: +30-21-7462186 Fax: +30-21-7462157
Received: September 16, 2014
Peer-review started: September 20, 2014
First decision: November 19, 2014
Revised: December 10, 2014
Accepted: December 29, 2014
Article in press: December 29, 2014
Published online: March 27, 2015
Core Tip

Core tip: Despite reduction of hepatitis C prevalence, hemodialysis (HD) patients still comprise a high risk group. HD individuals with chronic hepatitis C virus infection have lower aminotransferase and viral levels, milder histological features and a lower frequency of cirrhosis and hepatocellular carcinoma. However, liver disease is related to higher cardiovascular and all-cause mortality in this patient population. According to current recommendations, choice of treatment is interferon or pegylated interferon, whilst low doses of ribavirin also seem to have promising results. Data regarding new protease inhibitors are still lacking.